Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals' stock has experienced several events, including a reverse stock split in August 2025 to regain Nasdaq compliance. As of March 23, 2026, the stock price was $4.52, a 47.49% decrease over the past year, but it increased by 184.91% in the month leading up to that date. The company reported a net loss of $1.6 million for Q4 2025 and $8.0 million for the full year. Positive news included the granting of patents in Australia and Korea and positive Phase 2 clinical data for ibezapolstat, which led to a stock increase.

Acurx Pharmaceuticals does not currently have any marketed products or services, so there is no direct demand seasonality. Demand for its future products will be driven by medical need, regulatory approvals, and market adoption rather than seasonal fluctuations.

Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing antibacterial therapies for serious infections. Their lead product, ibezapolstat, is in Phase 2b trials for C. difficile infections, targeting the DNA polymerase IIIC enzyme. They also have ACX-375C in development, targeting other Gram-positive bacteria. Founded in 2017, the company went public in 2021.

Acurx Pharmaceuticals is headquartered in New York, with its operational footprint primarily in North America, focusing on clinical development activities. Future studies may include international locations, but the company does not currently maintain permanent offices or subsidiaries outside the United States.

Acurx Pharmaceuticals' brand reputation has been positively influenced by its scientific advancements, including new patents and the publication of structural evidence in Nature Communications. Positive Phase 2 clinical data for ibezapolstat has also boosted its reputation. However, the company's stock underperformance and continued net losses can negatively impact investor sentiment and reputation. Shareholder dilution has also been noted.

Acurx Pharmaceuticals has 19 institutional owners and shareholders, holding a total of 138,609 shares as of March 25, 2026. Individual insiders hold 4.5% of shares, institutions hold 8.59%, and the general public holds 86.9%.